Who here thinks NWBO could let cdf fund DCVax-l at cost until Eden? Once Eden up, NICE/MHRA fund approximately same price or somewhat more, but huge profit margin.
Anyone think this novel approach might work?
Remember, it is likely the Eden patients are experimental until equivalency approved.
It just seems like we have to account for LP’s ASM expressed NICE filing lag time. I think the above might explain it.
Market Data 
Markets 
AI
